Figure 1. Research Method Flow Chart 10
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 13
Figure 3. Asia-Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 15
Figure 4. Asia-Pacific Human Insulin Market, 2019-2026, $ mn 17
Figure 5. Primary Drivers and Impact Factors of Asia-Pacific Human Insulin Market 18
Figure 6. Primary Restraints and Impact Factors of Asia-Pacific Human Insulin Market 21
Figure 7. Porter’s Fiver Forces Analysis of Asia-Pacific Human Insulin Market 27
Figure 8. Breakdown of Asia-Pacific Human Insulin Market by Product Type, 2019-2026, % of Revenue 31
Figure 9. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Product Type, Value ($ mn) and Share (%) 32
Figure 10. Asia-Pacific Human Insulin Market: Human Insulin Drugs, 2019-2026, $ mn 33
Figure 11. Asia-Pacific Human Insulin Market: Human Insulin Delivery Devices, 2019-2026, $ mn 34
Figure 12. Breakdown of Asia-Pacific Human Insulin Drugs Market by Product, 2019-2026, % of Revenue 35
Figure 13. Contribution to Asia-Pacific Human Insulin Drugs Cumulative Revenue by Product, 2020-2026, Value ($ mn) and Share (%) 36
Figure 14. Asia-Pacific Human Insulin Market: Modern Human Insulin, 2019-2026, $ mn 37
Figure 15. Asia-Pacific Modern Human Insulin Market: Long-acting, 2019-2026, $ mn 39
Figure 16. Asia-Pacific Modern Human Insulin Market: Rapid- acting, 2019-2026, $ mn 40
Figure 17. Asia-Pacific Modern Human Insulin Market: Premixed, 2019-2026, $ mn 41
Figure 18. Asia-Pacific Modern Human Insulin Market: Lantus, 2019-2026, $ mn 42
Figure 19. Asia-Pacific Modern Human Insulin Market: Apidra, 2019-2026, $ mn 43
Figure 20. Asia-Pacific Modern Human Insulin Market: Levemir, 2019-2026, $ mn 44
Figure 21. Asia-Pacific Modern Human Insulin Market: NovoRapid/ NovoLog, 2019-2026, $ mn 45
Figure 22. Asia-Pacific Modern Human Insulin Market: Novomix, 2019-2026, $ mn 46
Figure 23. Asia-Pacific Modern Human Insulin Market: Humalog, 2019-2026, $ mn 47
Figure 24. Asia-Pacific Modern Human Insulin Market: Other Brands, 2019-2026, $ mn 48
Figure 25. Asia-Pacific Human Insulin Market: Traditional Human Insulin, 2019-2026, $ mn 49
Figure 26. Asia-Pacific Traditional Human Insulin Market: Short-acting, 2019-2026, $ mn 51
Figure 27. Asia-Pacific Traditional Human Insulin Market: Intermediate & Rapid-acting, 2019-2026, $ mn 52
Figure 28. Asia-Pacific Traditional Human Insulin Market: Premixed, 2019-2026, $ mn 53
Figure 29. Asia-Pacific Traditional Human Insulin Market: Humulin, 2019-2026, $ mn 54
Figure 30. Asia-Pacific Traditional Human Insulin Market: Insuman, 2019-2026, $ mn 55
Figure 31. Asia-Pacific Traditional Human Insulin Market: Novolin/Actrapid/Insulatard, 2019-2026, $ mn 56
Figure 32. Breakdown of Asia-Pacific Human Insulin Delivery Devices Market by Product, 2019-2026, % of Revenue 57
Figure 33. Contribution to Asia-Pacific Human Insulin Delivery Devices Cumulative Revenue by Product, 2020-2026, Value ($ mn) and Share (%) 58
Figure 34. Asia-Pacific Human Insulin Delivery Devices Market: Syringes, 2019-2026, $ mn 59
Figure 35. Asia-Pacific Human Insulin Delivery Devices Market: Pens, 2019-2026, $ mn 60
Figure 36. Asia-Pacific Human Insulin Delivery Devices Market: Pumps, 2019-2026, $ mn 61
Figure 37. Asia-Pacific Human Insulin Delivery Devices Market: Other Devices, 2019-2026, $ mn 63
Figure 38. Breakdown of Asia-Pacific Human Insulin Market by Application, 2019-2026, % of Revenue 64
Figure 39. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Application, Value ($ mn) and Share (%) 65
Figure 40. Asia-Pacific Human Insulin Market: Type 1 Diabetes, 2019-2026, $ mn 66
Figure 41. Asia-Pacific Human Insulin Market: Type 2 Diabetes, 2019-2026, $ mn 67
Figure 42. Asia-Pacific Human Insulin Market: Gestational Diabetes and Prediabetes, 2019-2026, $ mn 68
Figure 43. Breakdown of Asia-Pacific Human Insulin Market by Distribution Channel, 2019-2026, % of Revenue 69
Figure 44. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%) 70
Figure 45. Asia-Pacific Human Insulin Market: Hospital Pharmacies, 2019-2026, $ mn 71
Figure 46. Asia-Pacific Human Insulin Market: Retail Pharmacies, 2019-2026, $ mn 72
Figure 47. Asia-Pacific Human Insulin Market: Online Pharmacies, 2019-2026, $ mn 73
Figure 48. Breakdown of APAC Human Insulin Market by Country, 2019 and 2026, % of Revenue 75
Figure 49. Contribution to APAC 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 76
Figure 50. Human Insulin Market in Japan, 2019-2026, $ mn 78
Figure 51. Human Insulin Market in China, 2019-2026, $ mn 80
Figure 52. Human Insulin Market in Australia, 2019-2026, $ mn 82
Figure 53. Human Insulin Market in India, 2019-2026, $ mn 84
Figure 54. Human Insulin Market in South Korea, 2019-2026, $ mn 86
Figure 55. Human Insulin Market in Rest of APAC, 2019-2026, $ mn 88
Figure 56. Growth Stage of Asia-Pacific Human Insulin Industry over the Forecast Period 90
Asia Pacific human insulin market will grow by 9.74% annually over forecast years with a total addressable market cap of $66.02 billion for 2020-2026. Highlighted with 37 tables and 56 figures, this 113-page report “Asia Pacific Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify Asia Pacific human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country. Based on product type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Human Insulin Drugs • Human Insulin Delivery Devices Based on product, the Asia Pacific Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand) • Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand) Based on product, the Asia Pacific Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Syringes • Pens (further segmented into Disposable, Reusable, Pen needles) • Pumps • Others Based on application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Type 1 Diabetes • Type 2 Diabetes • Gestational Diabetes and Prediabetes Based on distribution channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific human insulin market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players: Astra Zeneca PLC Biocon Eli Lilly Exir Julphar Novo Nordisk AS Pfizer Sanofi Aventis Sedico Wockhardt (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More